Literature DB >> 2037795

Chronic Cryptosporidium parvum infections in congenitally immunodeficient SCID and nude mice.

J R Mead1, M J Arrowood, R W Sidwell, M C Healey.   

Abstract

Severe combined immune deficient (SCID) and athymic National Institutes of Health (NIH)-III (bg/nu/xid) mice were evaluated for susceptibility to Cryptosporidium parvum infections as neonates and as adults after challenge with inocula of 5 x 10(4) and 1 x 10(6) oocysts/mouse, respectively. SCID and NIH-III nude mice developed chronic infections that persisted over 12 weeks. Cryptosporidial organisms were observed in the small and large intestines of all mice. Colonization of the gallbladder and hepatobiliary duct epithelium occurred in a majority of the NIH-III nude mice and a smaller number of the SCID mice. Severe infections in both mouse strains were associated with clinical deterioration followed by death. Signs in these mice included dehydration, icterus, and emaciation. Deaths apparently resulted from hepatic dysfunction. Control mice experienced transient infections with no clinical signs. Immunodeficient mice should prove useful in studies of disease pathogenesis and in evaluating potential anticryptosporidial agents.

Entities:  

Mesh:

Year:  1991        PMID: 2037795     DOI: 10.1093/infdis/163.6.1297

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

Review 1.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

2.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

4.  Cloning and expression of a cDNA encoding epitopes shared by 15- and 60-kilodalton proteins of Cryptosporidium parvum sporozoites.

Authors:  M C Jenkins; R Fayer; M Tilley; S J Upton
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

5.  Putative anticryptosporidial agents tested with an immunodeficient mouse model.

Authors:  G J Leitch; Q He
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Comparison of Cryptosporidium parvum and Cryptosporidium wrairi by reactivity with monoclonal antibodies and ability to infect severe combined immunodeficient mice.

Authors:  C E Chrisp; P Mason; L E Perryman
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Experimental Cryptosporidium parvum infections in immunosuppressed adult mice.

Authors:  K R Rasmussen; M C Healey
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Requirements for CD4+ cells and gamma interferon in resolution of established Cryptosporidium parvum infection in mice.

Authors:  W Chen; J A Harp; A G Harmsen
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

9.  Effect of orally administered monoclonal antibody on persistent Cryptosporidium parvum infection in scid mice.

Authors:  L E Perryman; K A Kegerris; P H Mason
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.

Authors:  M W Riggs; V A Cama; H L Leary; C R Sterling
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.